Symbyax

 

Topic mentions per year

Topic mentions per year

2004-2017
01220042017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
  • 2017
• Efficacy was established with Symbyax (olanzapine and HIGHLIGHTS OF PRESCRIBING INFORMATION fluoxetine in combination) in… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Review
2013
Review
2013
INTRODUCTION A proprietary combination of the atypical antipsychotic drug olanzapine and the serotonin reuptake inhibitor… (More)
Is this relevant?
2011
2011
Diseases that disproportionally afflict the world’s poor provide few incentives for profitseeking drug companies. In the past… (More)
Is this relevant?
Review
2010
Review
2010
Treatment resistance is frequently encountered during the long-term care of patients with major depression. A number of 'next… (More)
Is this relevant?
Review
2010
Review
2010
Olanzapine/fluoxetine (Symbyax) is an oral, once-daily, fixed-dose combination of the atypical antipsychotic olanzapine and the… (More)
Is this relevant?
Review
2009
Review
2009
Many patients fail to achieve an adequate response to antidepressant medication. Growing evidence suggests that atypical… (More)
Is this relevant?
Review
2008
Review
2008
Olanzapine/fluoxetine (Symbyax) is an oral once-daily fixed-dose combination of the atypical antipsychotic olanzapine and the… (More)
Is this relevant?
Review
2008
Review
2008
Olanzapine/fluoxetine (Symbyax) is an oral once-daily fixed-dose combination of the atypical antipsychotic olanzapine and the… (More)
Is this relevant?
2005
2005
The depressive phase of bipolar disorder (bipolar depression) is a difficult-to-treat form of depression. The olanzapine… (More)
  • figure 1
  • figure 3
  • figure 2
  • table 1
Is this relevant?
2004
2004
  • The Medical letter on drugs and therapeutics
  • 2004
 
Is this relevant?